Bone Morphogenetic Protein-7 Signals Opposing Transforming Growth Factor β in Mesangial Cells*

Bone morphogenetic protein-7 (BMP7) is expressed in adult kidney and reduces renal fibrogenesis when given exogenously to rodents with experimental chronic nephropathies. In mesangial cells that regulate glomerular fibrosis in vivo, BMP7 inhibits transforming growth factor β (TGF-β)-driven fibrogenesis, primarily by preventing the TGF-β-dependent down-regulation of matrix degradation and up-regulation of PAI-1. The signals and mechanisms of the BMP7 opposition to actions of TGF-β are unknown. Here we show in mesangial cells that BMP7 reduces nuclear accumulation of Smad3 and blocks the transcriptional up-regulation of the TGF-β/Smad3 target, CAGA-lux. Smad5 knock-down impairs the ability of BMP7 to interfere with the activation of CAGA-lux and the accumulation of PAI-1 by TGF-β indicating that Smad5 is required. Smad5 knock-down also reduces the rise in Smad6 upon BMP7. Forced expression of smad5 (found to be the preferred BMP7-induced receptor-activated Smad signal in mesangial cells) or of smad6 mimics BMP7 in opposing the increase in transcriptional activation of PAI-1 and its secretion upon TGF-β. This suggests a model for the BMP7-induced opposition to TGF-β-dependent mesangial fibrogenesis requiring Smad5; the model involves the inhibitory Smad6 downstream of Smad5 as well as reduced availability of Smad3 in the nucleus. BMP7 does not require signaling through Erk1/2, p38, or JNK and does not utilize the TGF-β transcriptional co-repressors Ski or SnoN in mesangial cells. These studies provide first insights into mechanisms through which BMP7 opposes TGF-β-induced glomerular fibrogenesis.

[1]  R. Kalluri,et al.  BMP-7 counteracts TGF-β1–induced epithelial-to-mesenchymal transition and reverses chronic renal injury , 2003, Nature Medicine.

[2]  M. Estacion,et al.  Blockade of maitotoxin-induced endothelial cell lysis by glycine and L-alanine. , 2003, American journal of physiology. Cell physiology.

[3]  C. Hill,et al.  Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. , 2002, Molecular cell.

[4]  R. Kucherlapati,et al.  Functional Characterization of Transforming Growth Factor β Signaling in Smad2- and Smad3-deficient Fibroblasts* , 2001, The Journal of Biological Chemistry.

[5]  J. Massagué,et al.  Smad Transcriptional Corepressors in TGFβ Family Signaling , 2001 .

[6]  Denis Vivien,et al.  Direct binding of Smad3 and Smad4 to critical TGFβ‐inducible elements in the promoter of human plasminogen activator inhibitor‐type 1 gene , 1998, The EMBO journal.

[7]  K. Miyazono,et al.  Two Short Segments of Smad3 Are Important for Specific Interaction of Smad3 with c-Ski and SnoN* 210 , 2003, The Journal of Biological Chemistry.

[8]  H. Schnaper,et al.  Cross‐talk between ERK MAP kinase and Smad‐signaling pathways enhances TGF‐β dependent responses in human mesangial cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  S. Kuersten,et al.  Nucleocytoplasmic transport: Ran, beta and beyond. , 2001, Trends in cell biology.

[10]  S. Hubchak,et al.  TGF-beta1 activates MAP kinase in human mesangial cells: a possible role in collagen expression. , 1999, Kidney international.

[11]  J. Campisi,et al.  Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  K. Lyons,et al.  A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. , 1995, Genes & development.

[13]  F. Verrecchia,et al.  5-fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation. , 2003, Molecular pharmacology.

[14]  D. Abraham,et al.  Connective Tissue Growth Factor Gene Regulation , 2003, The Journal of Biological Chemistry.

[15]  R. Derynck,et al.  Roles of Autocrine TGF-β Receptor and Smad Signaling in Adipocyte Differentiation , 2000, The Journal of cell biology.

[16]  J. Massagué,et al.  A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. , 1999, Genes & development.

[17]  G. Striker,et al.  Glomerular epithelial, mesangial, and endothelial cell lines from transgenic mice. , 1988, Kidney international.

[18]  J. Massagué,et al.  TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders , 2000, Cell.

[19]  H. Lodish,et al.  A Novel Nuclear Export Signal in Smad1 Is Essential for Its Signaling Activity* , 2003, Journal of Biological Chemistry.

[20]  H. Lodish,et al.  Nucleocytoplasmic Shuttling of Smad1 Conferred by Its Nuclear Localization and Nuclear Export Signals* , 2001, The Journal of Biological Chemistry.

[21]  K. Miyazono,et al.  Signal transduction by bone morphogenetic proteins. , 1998, Cytokine & growth factor reviews.

[22]  J. Lapage,et al.  Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. , 2001, Journal of the American Society of Nephrology : JASN.

[23]  D. Rifkin,et al.  An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. , 1994, Analytical biochemistry.

[24]  K. Miyazono,et al.  Smad6 Is a Smad1/5-induced Smad Inhibitor , 2000, The Journal of Biological Chemistry.

[25]  Jeffrey L. Wrana,et al.  Signal Transduction by the TGF-β Superfamily , 2002, Science.

[26]  F. Luyten,et al.  Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Roberts,et al.  Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. , 2003, Biochemical and biophysical research communications.

[28]  S. Klahr,et al.  Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. , 2003, Kidney international.

[29]  Sarah B Tegen,et al.  The Transforming Activity of Ski and SnoN Is Dependent on Their Ability to Repress the Activity of Smad Proteins* , 2003, Journal of Biological Chemistry.

[30]  Chul-woo Yang,et al.  Bone Morphogenetic Protein-7 Inhibits Constitutive and Interleukin-1β-Induced Monocyte Chemoattractant Protein-1 Expression in Human Mesangial Cells: Role for JNK/AP-1 Pathway 1 , 2003, The Journal of Immunology.

[31]  K. Miyazono,et al.  Divergence and convergence of TGF‐β/BMP signaling , 2001, Journal of cellular physiology.

[32]  Su‐Li Cheng,et al.  Signal Transductions Induced by Bone Morphogenetic Protein-2 and Transforming Growth Factor-β in Normal Human Osteoblastic Cells* , 2002, The Journal of Biological Chemistry.

[33]  D. Warburton,et al.  Smad7 is a TGF-β-inducible attenuator of Smad2/3-mediated inhibition of embryonic lung morphogenesis , 2000, Mechanisms of Development.

[34]  K. Miyazono,et al.  Smad6 inhibits signalling by the TGF-β superfamily , 1997, Nature.

[35]  H. Friess,et al.  Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. , 1999, Biochemical and biophysical research communications.

[36]  K. Flanders,et al.  Is Smad3 a major player in signal transduction pathways leading to fibrogenesis? , 2001, Chest.

[37]  S. Vukicevic,et al.  Characterization of receptors for osteogenic protein-1/bone morphogenetic protein-7 (OP-1/BMP-7) in rat kidneys. , 2000, Kidney international.